hotspot -WSS

hotspot

author：comprehensive 2025-09-29 23:12:29 - browse：865

An army of wooden figures under blue and pink lighting — biotech coverage from STAT — Adobe

Biotech startup ReNAgade Therapeutics is cutting staff just seven months after raising the largest Series A round in the industry this year.

ReNAgade launched in May with hopes of becoming a one-stop shop for medicines targeting RNA, the genetic blueprints that cells use to make proteins instrumental in numerous diseases. These types of medicines are in high demand following the advent of mRNA vaccines for Covid and RNA-silencing therapies made by companies like Alnylam Pharmaceuticals.

ReNAgade was able to capitalize on that excitement when it raised a $300 million Series A round led by MPM Capital’s BioImpact Capital and F2 Ventures. But in recent days, the company decided to lay off around 10% of its 100-person team, according to a company statement and former employees’ posts on social media.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Bernie Sanders bashes nonprofit hospitals over their tax breaks

explore

entertainment

WSS

Wellcome Trust names Røttingen as its new CEO

Akero's treatment for NASH falls short in cirrhosis study

Bird flu: Don't repeat Covid's 'health versus the economy' framing

Better Therapeutics data on benefit with GLP

Researchers CRISPR chickens in bid to protect them from bird flu

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

entertainment

hotspot

knowledge

Jerome Adams on the need for new antivirals for Covid

Akero's treatment for NASH falls short in cirrhosis study

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Wearables generate powerful data but its not useful to doctors, yet

Trump demands the U.S. pay no more for drugs than other countries … again

Helping hospitals and community health centers plan for resilience

Walensky prepares to leave CDC — and Congress — behind

Readers respond to H5N1 and livestock movements, and more

In Memoriam: Notable people who died in 2023

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

focus

European regulators recommend Amylyx's ALS drug be rejected

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

Female surgeons have lower rates of long

Addiction experts warn against a second 'war on drugs'

Readout LOUD podcast: Merger Mondays, Ozempic panic

STAT Readout: Today's biotech news includes Sana and Amylyx

explore

focus

entertainment

knowledge